Genertec Universal Medical Group Company Limited
Genertec Universal Medical Group Company Limited Fundamental Analysis
Genertec Universal Medical Group Company Limited (UMTAF) shows moderate financial fundamentals with a PE ratio of 4.15, profit margin of 15.73%, and ROE of 12.80%. The company generates $11.9B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 34.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze UMTAF's fundamental strength across five key dimensions:
Efficiency Score
WeakUMTAF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentUMTAF trades at attractive valuation levels.
Growth Score
ModerateUMTAF shows steady but slowing expansion.
Financial Health Score
WeakUMTAF carries high financial risk with limited liquidity.
Profitability Score
ModerateUMTAF maintains healthy but balanced margins.
Key Financial Metrics
Is UMTAF Expensive or Cheap?
P/E Ratio
UMTAF trades at 4.15 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, UMTAF's PEG of 0.01 indicates potential undervaluation.
Price to Book
The market values Genertec Universal Medical Group Company Limited at 0.50 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -12.18 times EBITDA. This is generally considered low.
How Well Does UMTAF Make Money?
Net Profit Margin
For every $100 in sales, Genertec Universal Medical Group Company Limited keeps $15.73 as profit after all expenses.
Operating Margin
Core operations generate 88.07 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.80 in profit for every $100 of shareholder equity.
ROA
Genertec Universal Medical Group Company Limited generates $2.63 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genertec Universal Medical Group Company Limited generates strong operating cash flow of $4.43B, reflecting robust business health.
Free Cash Flow
Genertec Universal Medical Group Company Limited generates strong free cash flow of $3.63B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.92 in free cash annually.
FCF Yield
UMTAF converts 52.78% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
4.15
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.006
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.50
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.58
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
3.008
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.09
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.24
vs 25 benchmark
How UMTAF Stacks Against Its Sector Peers
| Metric | UMTAF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 4.15 | 18.66 | Better (Cheaper) |
| ROE | 12.80% | 804.00% | Weak |
| Net Margin | 15.73% | 2258.00% | Weak |
| Debt/Equity | 3.01 | 1.03 | Weak (High Leverage) |
| Current Ratio | 0.09 | 662.03 | Weak Liquidity |
| ROA | 2.63% | -24049.00% (disorted) | Weak |
UMTAF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genertec Universal Medical Group Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical